Spirapril

Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure[1][2][3].

Product Specifications

CAS Number

[83647-97-6]

Product Name Alternative

SCH 33844

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/spirapril.html

Solubility

10 mM in DMSO

Smiles

CCOC([C@H](CCC1=CC=CC=C1)N[C@@H](C)C(N2CC3(SCCS3)C[C@H]2C(O)=O)=O)=O

Molecular Formula

C22H30N2O5S2

Molecular Weight

466.61

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49 (5) :750-66.|[2]Maul B, et al. Alcohol consumption is controlled by angiotensin II. FASEB J. 2001 Jul;15 (9) :1640-2.|[3]Olivetti G, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21 (3) :362-70.